$VIGL
Vigil Neuroscience, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122802 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.904M
YoY Change -0.09%
% of Gross Profit
Research & Development $13.77M
YoY Change -10.66%
% of Gross Profit
Depreciation & Amortization $114.0K
YoY Change 3.64%
% of Gross Profit
Operating Expenses $20.68M
YoY Change -7.37%
Operating Profit -$20.68M
YoY Change -7.37%
Interest Expense $1.410M
YoY Change -22.95%
% of Operating Profit
Other Income/Expense, Net $1.418M
YoY Change -22.34%
Pretax Income -$19.26M
YoY Change -6.06%
Income Tax
% Of Pretax Income
Net Earnings -$19.26M
YoY Change -6.04%
Net Earnings / Revenue
Basic Earnings Per Share -$0.47
Diluted Earnings Per Share -$0.47
COMMON SHARES
Basic Shares Outstanding 40.88M 39.65M
Diluted Shares Outstanding 40.58M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $111.3M
YoY Change -16.71%
Cash & Equivalents $44.90M
Short-Term Investments $66.37M
Other Short-Term Assets $945.0K
YoY Change -15.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $113.7M
YoY Change -18.71%
LONG-TERM ASSETS
Property, Plant & Equipment $1.426M
YoY Change -22.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $103.0K
YoY Change -88.56%
Total Long-Term Assets $17.59M
YoY Change -8.91%
TOTAL ASSETS
Total Short-Term Assets $113.7M
Total Long-Term Assets $17.59M
Total Assets $131.3M
YoY Change -17.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $860.0K
YoY Change -33.95%
Accrued Expenses $9.677M
YoY Change 9.97%
Deferred Revenue $20.00M
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.55M
YoY Change 201.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $12.18M
YoY Change -7.77%
Total Long-Term Liabilities $12.18M
YoY Change -7.77%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.55M
Total Long-Term Liabilities $12.18M
Total Liabilities $42.72M
YoY Change 83.19%
SHAREHOLDERS EQUITY
Retained Earnings -$283.2M
YoY Change 41.18%
Common Stock $371.6M
YoY Change 10.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.55M
YoY Change
Total Liabilities & Shareholders Equity $131.3M
YoY Change -17.52%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$19.26M
YoY Change -6.04%
Depreciation, Depletion And Amortization $114.0K
YoY Change 3.64%
Cash From Operating Activities $4.301M
YoY Change -124.85%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$16.58M
YoY Change -207.93%
Cash From Investing Activities -$16.58M
YoY Change -208.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.86M
YoY Change 33001.67%
NET CHANGE
Cash From Operating Activities 4.301M
Cash From Investing Activities -16.58M
Cash From Financing Activities 19.86M
Net Change In Cash 7.584M
YoY Change -492.95%
FREE CASH FLOW
Cash From Operating Activities $4.301M
Capital Expenditures $0.00
Free Cash Flow $4.301M
YoY Change -124.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001827087
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member
CY2024Q3 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://www.vigilneuro.com/20240930#MarketableSecuritiesMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://www.vigilneuro.com/20240930#MarketableSecuritiesMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41200
dei Entity Registrant Name
EntityRegistrantName
VIGIL NEUROSCIENCE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1880494
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Forge Road,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
254-4445
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
VIGL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40879485
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44896000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51992000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
66373000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
65948000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2416000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3967000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
113685000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
121907000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1426000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1745000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15098000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16147000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
34000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
49000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
927000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
927000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
103000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
83000
CY2024Q3 us-gaap Assets
Assets
131273000
CY2023Q4 us-gaap Assets
Assets
140858000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
860000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1946000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20009000
CY2024Q3 vigl Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8675000
CY2023Q4 vigl Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8810000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1002000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
905000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30546000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11661000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12175000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12945000
CY2024Q3 us-gaap Liabilities
Liabilities
42721000
CY2023Q4 us-gaap Liabilities
Liabilities
24606000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
537634
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
537634
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39710322
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35929035
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39665999
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35884712
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
371635000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
339025000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
110000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283197000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222772000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
88552000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
116252000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131273000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140858000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13772000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15415000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43638000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44152000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6904000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6906000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20931000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20857000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
20676000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
22321000
us-gaap Operating Expenses
OperatingExpenses
64569000
us-gaap Operating Expenses
OperatingExpenses
65009000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20676000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22321000
us-gaap Operating Income Loss
OperatingIncomeLoss
-64569000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65009000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1410000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1829000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4141000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4560000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1418000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1826000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4144000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4545000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19258000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20495000
us-gaap Net Income Loss
NetIncomeLoss
-60425000
us-gaap Net Income Loss
NetIncomeLoss
-60464000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40577955
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40577955
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38809109
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38809109
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40336433
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40336433
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38671739
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38671739
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19258000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20495000
us-gaap Net Income Loss
NetIncomeLoss
-60425000
us-gaap Net Income Loss
NetIncomeLoss
-60464000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
136000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
115000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-56000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19122000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20481000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60310000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-60520000
CY2024Q3 vigl Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
0
vigl Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
0
CY2023Q3 vigl Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
0
vigl Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
50000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
189081000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
214000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1734000
CY2023Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
106000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-19795000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
171340000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
589000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2257000
CY2023Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-176000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20174000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
153836000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2426000
CY2023Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
14000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20495000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
135836000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
116252000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5183000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2312000
CY2024Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-25000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-19940000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
103782000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2704000
CY2024Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
4000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-21227000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
85272000
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19810000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2541000
CY2024Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
136000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19258000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
88552000
us-gaap Profit Loss
ProfitLoss
-60425000
us-gaap Profit Loss
ProfitLoss
-60464000
us-gaap Share Based Compensation
ShareBasedCompensation
7557000
us-gaap Share Based Compensation
ShareBasedCompensation
6417000
vigl Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1049000
vigl Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1023000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
340000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
286000
vigl Amortization Of Premium Discount On Marketable Securities
AmortizationOfPremiumDiscountOnMarketableSecurities
-1232000
vigl Amortization Of Premium Discount On Marketable Securities
AmortizationOfPremiumDiscountOnMarketableSecurities
-1772000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
16000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1551000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1945000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
20000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1086000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-639000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
20009000
vigl Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-137000
vigl Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1228000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-672000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-421000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33082000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54853000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
75092000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
117132000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
76029000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
42000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
661000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
932000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-75793000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
19810000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5184000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
23000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
858000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25054000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
835000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7096000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-129811000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52919000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
187532000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45823000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57721000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
14319000
vigl Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
2887000
CY2024Q3 vigl Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
111300000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283200000
CY2023Q1 vigl Maximum Stock Value To Be Issued Under Agreement
MaximumStockValueToBeIssuedUnderAgreement
100000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, research and development expenses and related prepaid or accrued costs and stock-based compensation. The Company bases its estimates on historical experience, known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44896000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56794000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
927000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
927000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45823000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57721000
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2024Q3 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2024Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
66263000
CY2024Q3 vigl Investment Unrealized Gain
InvestmentUnrealizedGain
114000
CY2024Q3 vigl Investment Unrealized Losses
InvestmentUnrealizedLosses
4000
CY2024Q3 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
66373000
CY2023Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
65953000
CY2023Q4 vigl Investment Unrealized Gain
InvestmentUnrealizedGain
36000
CY2023Q4 vigl Investment Unrealized Losses
InvestmentUnrealizedLosses
41000
CY2023Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
65948000
CY2024Q3 vigl Number Of Securities
NumberOfSecurities
30
CY2024Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
3
CY2024Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2024Q3 vigl Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
694000
CY2023Q4 vigl Prepaid Research And Development Expense Current
PrepaidResearchAndDevelopmentExpenseCurrent
1563000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
382000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
122000
CY2024Q3 us-gaap Interest Receivable
InterestReceivable
361000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
348000
CY2024Q3 us-gaap Other Receivables
OtherReceivables
34000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
1137000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
945000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
797000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2416000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3967000
CY2024Q3 vigl Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3987000
CY2023Q4 vigl Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
3278000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3687000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4208000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
835000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1000000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
166000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
324000
CY2024Q3 vigl Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8675000
CY2023Q4 vigl Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8810000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7600000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6400000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2541000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2426000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7557000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6417000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote for each share of common stock held.
CY2024Q3 us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q3 us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16657585
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10922405
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-19258000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-20495000
us-gaap Net Income Loss
NetIncomeLoss
-60425000
us-gaap Net Income Loss
NetIncomeLoss
-60464000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40577955
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40577955
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38809109
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38809109
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40336433
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40336433
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38671739
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38671739
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.5
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
vigl Pre Funded Warrants Remaining Unfunded Exercise Price
PreFundedWarrantsRemainingUnfundedExercisePrice
0.0001
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12930601
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6138962
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
14300000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17300000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1800000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2024Q3 us-gaap Variable Lease Payment
VariableLeasePayment
200000
us-gaap Variable Lease Payment
VariableLeasePayment
700000
CY2023Q3 us-gaap Variable Lease Payment
VariableLeasePayment
100000
us-gaap Variable Lease Payment
VariableLeasePayment
600000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0757
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
477000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1968000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2027000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2088000
CY2024Q3 vigl Lessee Operating Lease Liability Payments Due Year Five And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
11269000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17829000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4652000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13177000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
20000000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000

Files In Submission

Name View Source Status
0000950170-24-122802-index-headers.html Edgar Link pending
0000950170-24-122802-index.html Edgar Link pending
0000950170-24-122802.txt Edgar Link pending
0000950170-24-122802-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vigl-20240930.htm Edgar Link pending
vigl-20240930.xsd Edgar Link pending
vigl-ex31_1.htm Edgar Link pending
vigl-ex31_2.htm Edgar Link pending
vigl-ex32_1.htm Edgar Link pending
vigl-ex32_2.htm Edgar Link pending
vigl-20240930_htm.xml Edgar Link completed